BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lerochol (Lerodalcibep) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lerochol (Lerodalcibep)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07102511-1049@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07102511)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Study to Evaluate the Efficacy and Safety of Lerodalc
 ibep in Children 6 to 17 Years\, With Heterozygous FH\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07102511
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775339-1049@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07775339)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Long-Term Efficacy and Safety of Lerodalcibep in Chil
 dren and Adolescents With Familial Hypercholesterolemia\nEstimated primary
  completion: 31 July 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07775339
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
